View in EDS

Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.

Saved in:
Bibliographic Details
Title: Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.
Authors: Short NJ; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Kantarjian HM; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Daver NG; University of Texas, MD Anderson Cancer Center, Houston, Texas, United States., Azevedo RS; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Karrar O; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., DiNardo CD; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Kadia TM; MD Anderson Cancer Center, Houston, Texas, United States., Yilmaz M; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Maroun MM; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Hachem MCR; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Borthakur G; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Issa GC; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Shpall EJ; MD Anderson, Houston, Texas, United States., Popat UR; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Huang X; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Qiao W; MD Anderson Cancer Center, Houston, Texas, United States., Nasr LF; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Macaron W; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Abramova R; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Garcia-Manero G; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Konopleva M; Albert Einstein College of Medicine, New York, New York, United States., Ravandi F; University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States.
Source: Blood advances [Blood Adv] 2026 May 27. Date of Electronic Publication: 2026 May 27.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42200455
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Short+NJ%22">Short NJ</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Kantarjian+HM%22">Kantarjian HM</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Daver+NG%22">Daver NG</searchLink>; University of Texas, MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Azevedo+RS%22">Azevedo RS</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Karrar+O%22">Karrar O</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22DiNardo+CD%22">DiNardo CD</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Kadia+TM%22">Kadia TM</searchLink>; MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Yilmaz+M%22">Yilmaz M</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Maroun+MM%22">Maroun MM</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Hachem+MCR%22">Hachem MCR</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Borthakur+G%22">Borthakur G</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Issa+GC%22">Issa GC</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Shpall+EJ%22">Shpall EJ</searchLink>; MD Anderson, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Popat+UR%22">Popat UR</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Huang+X%22">Huang X</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Qiao+W%22">Qiao W</searchLink>; MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Nasr+LF%22">Nasr LF</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Macaron+W%22">Macaron W</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Abramova+R%22">Abramova R</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Garcia-Manero+G%22">Garcia-Manero G</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.<br /><searchLink fieldCode="AU" term="%22Konopleva+M%22">Konopleva M</searchLink>; Albert Einstein College of Medicine, New York, New York, United States.<br /><searchLink fieldCode="AU" term="%22Ravandi+F%22">Ravandi F</searchLink>; University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2026 May 27. <i>Date of Electronic Publication: </i>2026 May 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42200455
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2026019841
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Short NJ
      – PersonEntity:
          Name:
            NameFull: Kantarjian HM
      – PersonEntity:
          Name:
            NameFull: Daver NG
      – PersonEntity:
          Name:
            NameFull: Azevedo RS
      – PersonEntity:
          Name:
            NameFull: Karrar O
      – PersonEntity:
          Name:
            NameFull: DiNardo CD
      – PersonEntity:
          Name:
            NameFull: Kadia TM
      – PersonEntity:
          Name:
            NameFull: Yilmaz M
      – PersonEntity:
          Name:
            NameFull: Maroun MM
      – PersonEntity:
          Name:
            NameFull: Hachem MCR
      – PersonEntity:
          Name:
            NameFull: Borthakur G
      – PersonEntity:
          Name:
            NameFull: Issa GC
      – PersonEntity:
          Name:
            NameFull: Shpall EJ
      – PersonEntity:
          Name:
            NameFull: Popat UR
      – PersonEntity:
          Name:
            NameFull: Huang X
      – PersonEntity:
          Name:
            NameFull: Qiao W
      – PersonEntity:
          Name:
            NameFull: Nasr LF
      – PersonEntity:
          Name:
            NameFull: Macaron W
      – PersonEntity:
          Name:
            NameFull: Abramova R
      – PersonEntity:
          Name:
            NameFull: Garcia-Manero G
      – PersonEntity:
          Name:
            NameFull: Konopleva M
      – PersonEntity:
          Name:
            NameFull: Ravandi F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 05
              Text: 2026 May 27
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1